EUVIMEDEUVIMED entdecken
Crossref

Myricitrin promotes osteogenesis and prevents ovariectomy bone mass loss via the PI3K/AKT signalling pathway

Jianliang Li, Jiale Mai, Meng Zhang, Yanhuai Ma, Qi He, Dawei Gong, Jiacong Xiao, Miao Li, Weijian Chen, Zhen Li, Shuai Chen, Zhaofeng Pan und 2 weitere

Journal of Cellular Biochemistry · 2023

DOI: 10.1002/jcb.30439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2023. Verfasst von Jianliang Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: First School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China. Hauptthemen laut MEDLINE: Bone Diseases, Metabolic, Osteogenesis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to explore the effect of myricitrin on osteoblast differentiation in mice immortalised bone marrow mesenchymal stem cells (imBMSCs). Additionally, ovariectomy (OVX) mice were employed to examine the effect of myricitrin on bone trabecular loss in vivo. The effect of myricitrin on the proliferation of imBMSCs was evaluated using a cell counting kit‐8 assay. Alizarin red staining, alkaline phosphatase staining were performed to elucidate osteogenesis. Furthermore, qRT‐PCR and western blot determined the expression of osteo‐specific genes and proteins. To screen for candidate targets, mRNA transcriptome genes were sequenced using bioinformatics analyses. Western blot and molecular docking analysis were used to examine target signalling markers. Moreover, rescue experiments were used to confirm the effect of myricitrin on the osteogenic differentiation of imBMSCs. OVX mice were also used to estimate the delay capability of myricitrin on bone trabecular loss in vivo using western blot, micro‐CT, tartaric acid phosphatase (Trap) staining, haematoxylin and eosin staining, Masson staining and immunochemistry. In vitro, myricitrin significantly enhanced osteo‐specific genes and protein expression and calcium deposition. Moreover, mRNA transcriptome gene sequencing and molecular docking analysis revealed that this enhancement was accompanied by an upregulation of the PI3K/AKT signalling pathway. Furthermore, copanlisib, a PI3K inhibitor, partially reversed the osteogenesis promotion induced by myricitrin. In vivo, western blot, micro‐CT, hematoxylin and eosin staining, Masson staining, Trap staining and immunochemistry revealed that bone trabecular loss rate was significantly alleviated in the myricitrin low‐ and high‐dose groups, with an increased expression of osteopontin, osteoprotegerin, p‐PI3K and p‐AKT compared to the OVX group. Myricitrin enhances imBMSC osteoblast differentiation and attenuate bone mass loss partly through the upregulation of the PI3K/AKT signalling pathway. Thus, myricitrin has therapeutic potential as an antiosteoporosis drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Diseases, MetabolicOsteogenesisAnimalsFemaleMiceCell DifferentiationCells, CulturedEosine Yellowish-(YS)Molecular Docking SimulationOvariectomyPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, MessengerFlavonoids

Stichwörter der Autor:innen

PI3K/AKT signalling pathwaybone marrow mesenchymal stem cellsmyricitrinosteoporosis

Substanzen

Eosine Yellowish-(YS)Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, MessengermyricitrinFlavonoids

Autor:innen und Institutionen

  • First School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • The Laboratory of Orthopaedics and Traumatology of Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Guangzhou First People's Hospital, Second Affiliated Hospital of South China University of Technology, Guangzhou, China.
  • Eighth Clinical School of Guangzhou University of Chinese Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan, China.
  • Department of Orthopedics, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, China.
  • Department of Orthopaedic Surgery, Wendeng Orthopedic and Traumatologic Hospital of Shandong Province, Weihai, China.

ORCID-Profile: Haibin Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, J., Mai, J., Zhang, M., Ma, Y., He, Q., Gong, D., Xiao, J., Li, M., Chen, W., Li, Z., Chen, S., Pan, Z., Li, S., & Wang, H. (2023). Myricitrin promotes osteogenesis and prevents ovariectomy bone mass loss via the PI3K/AKT signalling pathway. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30439

Vancouver

Li J, Mai J, Zhang M, Ma Y, He Q, Gong D, et al. Myricitrin promotes osteogenesis and prevents ovariectomy bone mass loss via the PI3K/AKT signalling pathway. Journal of Cellular Biochemistry. 2023. doi:10.1002/jcb.30439

BibTeX
@article{Li2023,
  author = {Li, Jianliang and Mai, Jiale and Zhang, Meng and Ma, Yanhuai and He, Qi and Gong, Dawei and Xiao, Jiacong and Li, Miao and Chen, Weijian and Li, Zhen and Chen, Shuai and Pan, Zhaofeng and Li, Shaocong and Wang, Haibin},
  title = {Myricitrin promotes osteogenesis and prevents ovariectomy bone mass loss via the PI3K/AKT signalling pathway},
  journal = {Journal of Cellular Biochemistry},
  year = {2023},
  doi = {10.1002/jcb.30439}
}
Kostenlos starten →